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Background: Schisandra, a globally distributed plant, has been widely applied to health care products. Here, we
investigated the effects of dietary intake of Fructus Schisandrae chinensis (FSC), both aqueous and ethanolic
extracts (AqFSC, EtFSC), on serum/hepatic lipid contents in normal diet (ND)- and high-fat/cholesterol/bile salt diet
(HFCBD)-fed mice.
Methods: Male ICR mice were fed with ND or HFCBD, supplemented with 1 and 4% of AqFSC and EtFSC,
respectively, or 0.1% fenofibrate, for 13 days. Lipids were determined according to the manufacture’s instructions.
Results: EtFSC, but not AqFSC, significantly elevated hepatic triglyceride (TG) in mice fed with ND. Feeding mice
with HFCBD increased serum total cholesterol (TC), high density lipoprotein (HDL) and low density lipoprotein (LDL)
levels as well as alanine aminotransferase (ALT) activity. Supplementation with AqFSC, EtFSC or fenofibrate
significantly reduced hepatic TC and TG levels. However, AqFSC and EtFSC supplementation increased serum HDL
and LDL levels in mice fed with HFCBD. Fenofibrate increased serum HDL and reduced serum LDL contents in
hypercholesterolemic mice. EtFSC reduced, but fenofibrate elevated, serum ALT activity in both normal and
hypercholesterolemic mice. While fenofibrate reduced serum TC, TG, and HDL levels in mice fed with ND, it
increased serum HDL and reduced serum LDL and TC levels in mice fed with HFCBD. Hepatomegaly was found in
normal and hypercholesterolemic mice fed with diet supplemented with fenofibrate.
Conclusions: Feeding mice with AqFSC and EtFSC ameliorated the HFCBD-induced hepatic steatosis. In addition,
EtFSC may offer protection against hepatic injury in hypercholesterolemic mice.
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HepatomegalyBackground
Increasing incidence of coronary heart disease (CHD) and
peripheral vascular disease as well as fatty liver is a result of
hyperlipidemia caused by unhealthy lifestyle. The epidemic
is also partly due to the failure in introducing effective thera-
peutic intervention for hyperlipidemia and hepatoteatosis.
Hepatosteatosis, which is also called nonalcoholic fatty liver
disease (NAFLD), is characterized by lipid deposition within* Correspondence: siyuan-pan@163.com
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reproduction in any medium, provided the orhepatocytes in patients having no history of excessive alco-
hol consumption. Being coined as a refractory progressive
disease, NAFLD can develop into liver cirrhosis or hepato-
cellular carcinoma, as well as nonalcoholic steatohepatitis
(NASH) [1-3]. Therefore, the search for therapeutic inter-
ventions aimed at lowering lipid contents in blood and liver
has been an area of intensive research. Drugs that are cur-
rently available for lowering blood lipids reduced the cor-
onary artery disease mortality of 23% and cardiovascular
disease mortality of 19% in patients with dyslipidemia [4].
However, there are no effective drugs or therapeutic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing from hyperlipidemia. While chemical drugs are less
appealing for their potential adverse side effects, the use
of naturally-occurring ingredients, such as soy isoflavones,
soy foods, prebiotic fibres, pentoxifylline and silibinin and
plant medicine for prevention and/or treatment of NAFLD
and dyslipidemia has become increasingly popular [5-9].
Schisandra genus of about 25 species throughout the
world, at present, it are mainly distributed in northern
China. Fructus Schisandrae chinensis (FSC), which is the
fruit of Schisandra chinensis, is a traditional Chinese
herb used for thousands of years in China. Modern scientific
research has shown that FSC extract or its active ingredient
(schisandrin B) and other related compounds (bifendate,
and bicyclol) possess a wide spectrum of biological activities,
particularly in protecting against chemically- and virally-
induced hepatitis [10-13]. In addition, previous studies in
our laboratory have shown that both FSC extract and the ac-
tive compounds (schisandrin B, bifendate and bicyclol)
reduced hepatic triglyceride (TG) and total cholesterol (TC)
levels in mice with hypercholesterolemia produced by high-
fat diet containing cholesterol/bile salt [14-17]. In the
present study, we endeavored to investigate the effects of
dietary supplementation with aqueous or ethanolic extract
of FSC on serum and hepatic lipid contents, with attention
to hepatotoxicity, in normal and hypercholesterolemic mice.
Fenofibrate was also used as a positive control for compari-
son. The objective of this study is to establish a pharmaco-
logical basis for the potential application of FSC in the
treatment of NAFLD and NASH.
Results
Serum lipid profiles
Supplementation with AqFSC and EtFSC at a dose of 1 or
4% did not affect serum levels of TC, TG, HDL, and LDL
in mice fed with ND. However, both AqFSC and EtFSC
significantly increased serum HDL and LDL levels (by 6–
13% and 31–47%, respectively) in hypercholesterolemic
mice. But they did not affect the serum TC and TG levels.
HFCBD markedly increased serum TC, HDL and LDL
levels (by 119, 19, and 494%, respectively) in mice. How-
ever, the serum TG level was decreased by 74%. On the
other hand, fenofibrate treatment reduced serum TC
(31%), TG (29%), and HDL (32%) levels in normal mice.
While the serum HDL level was elevated by 29%, TC and
LDL levels were reduced by 39 and 57%, respectively, in
mice fed HFCBD/fenofibrate-supplemented diet, when
compared with those fed with HFCBD only (Table 1).
Hepatic lipid contents and hepatic index
Feeding mice with 4% EtFSC with ND for 13 days sig-
nificantly increased hepatic TG content by 46%. While
0.1% fenofibrate with normal diet reduced hepatic TCand TG contents (by 56 and 60%, respectively), it
increased the hepatic index by 70%. Feeding mice with
HFCBD markedly increased hepatic TC and TG con-
tents as well as liver weight (by 560, 566, and 41%, re-
spectively), when compared with those of mice fed with
ND. Supplementation with AqFSC or EtFSC at concentra-
tion of 1 or 4% decreased the hepatic TC and TG contents
by 23–43 and 56–74%, respectively, in HFCBD-fed mice.
Fenofibrate treatment reduced hepatic TC and TG
contents (by 58 and 80%, respectively) in HFCBD-
fed mice, but it increased the hepatic index by 62%
(Figures 1 and 2).
Hepatotoxicity
Feeding mice with diet supplemented with 4% EtFSC
lowered serum ALT, but not AST, activity (up to 13%)
(p < 0.05) in normal mice. HFCBD caused increase in
serum ALT (by 169%) and AST (by 61%) activities in
mice. Supplementation with EtFSC, but not AqFSC,
decreased serum ALT and AST activity (up to 40%) in
HFCBD-fed mice. Dietary supplementation with fenofi-
brate increased serum ALT and AST activities in mice
fed with ND and HFCBD diet (Figure 3).
Weigh gain and food/drug intake
No detectable differences in body weight gain between
AqFSC/EtFSC supplemented and unsupplemented mice
fed with ND and HFCBD were observed. However,
weight loss was observed in fenofibrate supplemented
mice with ND (by 17.2%) and HFCBD (by 12.5%). Daily
intake of AqFSC/EtFSC was estimated to be 1.35–
1.99 g/kg (based on crude herb equivalent) at 1% supple-
mentation and 5.43–6.68 g/kg at 4% supplementation
(Table 2). The daily intake of fenofibrate was estimated
to be 0.17 g/kg.
Acute toxicity
In the acute toxicity test, either AqFSC or EtFSC was
administered intragastrically at increasing doses (24.5–
71.6 g/kg) and the mortality rate was determined within
48 h post-dosing in mice. LD50 value of AqFSC and
EtFSC was estimated to be 43.24 ± 7.79 g/kg and
40.35 ± 6.22, respectively, using the Bliss method.
Discussion
Hyperlipidemia, which can be broadly categorized into
hypercholesterolemia, hypertriglyceridemia and mixed
hyperlipidemia, is causally related to the pathogenesis of
CHD, cerebrovascular diseases, peripheral vascular dis-
ease and pancreatitis [18-21]. One major cause hyperlip-
idemia is unhealthy eating habit. In the present study,
both serum and hepatic lipid levels were notably ele-
vated in mice fed with HFCBD, a high-fat diet used in
Table 1 Effects of dietary supplementation with AqFSC, EtFSC, or fenofibrate on serum lipid profiles in normal and
hypercholesterolemic mice
Groups TC (mmo1/L) TG (mmo1/L) HDL (mmo1/L) LDL (mmo1/L)
Normal diet for 13 days
Normal diet 5.13 ± 0.18 1.84 ± 0.11 4.14 ± 0.14 0.33 ± 0.02
1% AqFSC/normal diet 4.90 ± 0.13 1.84 ± 0.08 4.13 ± 0.12 0.38 ± 0.04
4% AqFSC/normal diet 4.86 ± 0.16 2.03 ± 0.12 4.13 ± 0.16 0.38 ± 0.03
1% EtFSC/normal diet 4.89 ± 0.21 1.73 ± 0.07 4.01 ± 0.16 0.38 ± 0.02
4% EtFSC/normal diet 4.89 ± 0.17 1.77 ± 0.10 4.00 ± 0.12 0.39 ± 0.02
0.1% Fenofibrate/normal diet 3.54 ± 0.34* 1.30 ± 0.12* 2.80 ± 0.18* 0.39 ± 0.03
HFCB diet for 13 days
Normal diet 3.97 ± 0.24 1.19 ± 0.15 3.86 ± 0.12 0.33 ± 0.03
HFCB diet 8.71 ± 0.82* 0.31 ± 0.04* 4.59 ± 0.11* 1.96 ± 0.16*
1% AqFsSC/HFCB diet 7.01 ± 0.31 0.66 ± 0.05 5.17 ± 0.25† 2.87 ± 0.24†
4% AqFSC/HFCB diet 6.62 ± 0.24 0.27 ± 0.03 5.16 ± 0.18† 2.56 ± 0.14†
1% EtFSC/HFCB diet 8.63 ± 0.68 0.26 ± 0.03 4.87 ± 0.14† 2.68 ± 0.10†
4% EtFSC/HFCB diet 9.35 ± 0.37 0.27 ± 0.03 5.16 ± 0.12† 2.89 ± 0.27†
0.1% Fenofibrate/HFCB diet 5.30 ± 0.21† 0.67 ± 0.04 5.91 ± 0.32† 0.85 ± 0.15†
Mice were fed with either normal or high-fat/cholesterol/bill salt (HFCB, 10/1/0.3%, w/w) diet without and with supplementation with the aqueous/ethanolic
extract of Fructus Schisandrae chinensis (AqFSC/EtFSC) or fenofibrate at the indicated concentration for 13 days. The concentrations of AqFSC and EtFSC were
based on crude herbal material. Serum total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), and low density lipoprotein (LDL) levels were then
measured. Values given are the men± S.E.M., with n = 10. *Significantly different from the normal diet group (p< 0.05–0.001). †significantly different from the
hypercholesterolemic mice (p < 0.05–0.001).
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cholesteryl ester transfer protein, hepatic TG lipase and
lipoprotein lipase etc., the increased HDL and LDL
levels may be an event secondary to hypercholesterol-
emia induced by feeding HFCBD in mice. In this con-
nection, Guay et al. found that the cholesterol-elevating
effect of a high-fat diet was associated with the forma-
tion of larger LDL particles than those of a low-fat diet
[22]. It is well known that LDL is formed from very LDL
(VLDL) which secretes from liver and allows the supply
of triglycerides to tissues. However, it is not clear as to
why feeding mice with HFCBD resulted in low serum
TG levels [14-16,23]. Lipogenic activity appears to be
up-regulated in obese condition and serum triglyceride
is consumed for lipid synthesis, so serum TG decreased,
but the obese did not found in the mice fed with a high-
fat diet. In clinical situation, blood TG levels in patients
with hypercholesterolemia are not lower than those of
normal individuals. Therefore, the mouse model of
hypercholesterolemia, as adopted in the present study,
may be different from hypercholesterolemia in human
patients in the pathogenesis of the disease state. The ap-
parent liver injury induced by feeding HFCBD is likely
related to the accumulation of fat in hepatic tissue
[24,25]. In addition, hyperlipidemia is usually concerned
hyperglycemia and hyperinsulinemia caused by insulin
resistance in clinic [26], but in the present study, serumglucose levels were no significant differences between
model group and normal mice (data not shown). This
may be related to the short-time modeling (13 days).
Fenofibrate, a fibric acid derivative, is used to treat se-
vere hypertriglyceridemia and mixed dyslipidemia (i.e.,
increases both TC and TG levels in blood) in patients
who did not respond to non-pharmacological interven-
tion, of which the condition is usually associated with an
increased risk of atherosclerosis and/or fatty liver [27].
Fenofibrate treatment was found to reduce serum TG
and LDL levels, but increase HDL level in hyperlipid-
emic patients [28]. In the present study, fenofibrate sup-
plementation decreased serum TC, TG, and HDL levels
in ND-fed mice. The reduction of HDL level by fenofi-
brate may result from the drug-induced reaction second-
ary to hypolipidemic action [29]. In addition, liver injury
and hepatomegaly induced or aggravated by fenofibrate
treatment were observed in ND and HFCBD-fed mice.
Although fenofibrate treatment improved the hepatic
microcirculatory patency and oxygen availability in a
high-fat diet-induced fatty liver in mice as well as sup-
pressed the growth of human hepatocellular carcinoma
cells in vitro, it caused DNA damage in rat livers and
promoted hepatocarcinogenesis through increasing oxida-
tive stress in rodents [30-33]. Furthermore the long-term
and high-dose administration of fenofibrate caused liver



















































































Figure 1 Effects of dietary supplementation with AqFSC, EtFSC,
or fenofibrate on hepatic lipid contents in normal and
hypercholesterolemic mice. Mice were fed with a normal or
high-fat diet without and with supplementation with the drugs for
13 days. Experimental details were described in Table 1. Hepatic
total cholesterol (TC) and triglyceride (TG) levels were then
measured. Values given are the mean± S.E.M., with n = 10.
*Significantly different from the normal diet group (p < 0.05–0.001);





























Figure 2 Effects of dietary supplementation with AqFSC, EtFSC,
or fenofibrate on hepatic weight in normal and
hypercholesterolemic mice. Mice were fed with a normal or
high-fat diet without and with supplementation with the drugs for
13 days. Experimental details were described in Table 1. Hepatic
index was estimated from the ratio of total liver weight to body
weight. Values given are the mean± S.E.M., with n = 10. *Significantly
different from the normal diet group (p< 0.001); †significantly








































































Figure 3 Effects of dietary supplementation with AqFSC, EtFSC,
or fenofibrate on liver function in normal and
hypercholesterolemic mice. Mice were fed with a normal or
high-fat diet without and with supplementation with the drugs for
13 days. Experimental details were described in Table 1. Serum
alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
activity were then measured. Values given the mean± S.E.M., with
n = 10. *Significantly different from the normal diet group
(p< 0.05–0.001); †significantly different from the
hypercholesterolemic mice (p< 0.05–0.001).
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a daily dose of 300 mg in adult patients (i.e., 5 mg/kg/day
for 60 kg). The dose (180 mg/kg in ND-fed mice and
170 mg/kg in HFCBD-fed mice) adopted in the present
study is about 35–fold higher than the human dose.
Despite recent advances in the understanding of
hyperlipidemia and its associated adverse clinical out-
comes, hyperlipidemia remains the major cause of mor-
bidity and mortality throughout the world. While chemical
drugs are potent in lowering lipid levels in blood, they also
produce some side effects in patients who require life-long
medication. Recently, a shift from drug therapy to dietary
supplementation with naturally-occurring ingredients has
become a trend in the management of hyperlipidemia and
fatty liver disease. Medicinal plants have been used for over
millennia and are highly esteemed all over the world as a
rich source of therapeutic agents, food supplements and/or
additives for the prevention and treatment of diseases.
FSC, which is a commonly used Chinese herb, was tested
in the mouse model of hypercholesterolemia. Although
Table 2 Effects of dietary supplementation of AqFSC, EtFSC, or fenofibrate on body weight gain and food/drug intake
in the normal and hypercholesterolemic mice
Groups Body weight gain (g) Body-liver weight (g) Food intake (g/mouse/day) Drug intake (g/kg/day)
Normal diet for 13 days
Normal diet 8.55 ± 0.11 24.64 ± 0.36 4.20
1% AqFSC/normal diet 8.11 ± 0.19 24.63 ± 0.63 4.55 1.45
4% AqFSC/normal diet 8.05 ± 0.34 24.15 ± 0.58 4.32 5.56
1% EtFSC/normal diet 8.31 ± 0.15 24.53 ± 0.43 4.43 1.35
4% EtFSC/normal diet 8.45 ± 0.25 24.38 ± 0.43 4.21 5.43
0.1% Fenofibrate/normal diet 5.09 ± 0.08* 20.40 ± 0.28* 4.53 0.18
HFCB diet for 13 days
Normal diet 8.00 ± 0.43 25.72 ± 0.63 4.31 -
HFCB diet 7.52 ± 0.25 24.96 ± 0.54 3.85 -
1% AqFSC/HFCB diet 8.23 ± 0.67 24.76 ± 0.59 4.56 1.59
4% AqFSC/HFCB diet 7.96 ± 0.42 25.49 ± 0.63 4.89 6.68
1% EtFSC/HFCB diet 8.80 ± 0.35 25.29 ± 0.76 5.50 1.99
4% EtFSC/HFCB diet 8.71 ± 0.52 25.25 ± 0.72 4.23 6.13
0.1% Fenofibrate/HFCB diet 7.33 ± 0.32 22.51 ± 0.72† 4.31 0.17
Experimental details were described in Table 1. The dosages (g/kg/day) based on crude herbal material were determined with respect to the amount of ingested
diet (g/day/kg) and drug concentrations in the diet. Values given are the mean ± S.E.M., with n = 10.
*Significantly different from the normal diet group (p< 0.01); †significantly different from the hypercholesterolemic mice (p< 0.01).
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TG contents and elevated serum HDL and LDL levels in
mice fed with HFCBD, no significant differences in serum
lipid levels were observed in mice fed with normal diet
supplemented with AqFSC and EtFSC. This suggested that
the effect of FSC on lipids may be dependent on basal lipid
levels in the body. Under normal conditions, FSC did not
affect the serum lipid levels, but it exaggerated the eleva-
tion of serum HDL and LDL by HFCBD. It is well known
that HDL and LDL are “good cholesterol” and “bad choles-
terol” with respect to their role in the development of
CHD [37-39]. Whether or not dietary FSC-induced in-
crease in both HDL and LDL levels is “good” or “bad”
remains to be investigated.
Both AqFSC and EtFSC alleviated the accumulation of
lipids in livers of HFCB diet-fed mice, but only EtFSC sup-
pressed the serum ALT activity, a biochemical index of
liver damage. The inability of AqFSC to protect against
liver damage in hypercholesterolemic mice may be related
to the possibility that the anti-fatty liver ingredients, which
are present in both AqFSC and EtFSC, are distinct from
those for liver protection, with the latter being present in
EtFSC only. As EtFSC also inhibited serum ALT activity in
ND-fed mice, the direct inhibition of EtFSC on ALT activ-
ity cannot be excluded. The hepatoprotective effect of
EtFSC can be confirmed by the measurement of alterna-
tive housekeeping enzymes like sorbitol dehydrogenase in
the blood and/or histological analysis of liver tissue. Lig-
nans are currently considered as hepatoprotective ingredi-
ents in FSC by virtue of their in vivo antioxidant potential[40,41]. The fat-soluble lignans likely reside in EtFSC ra-
ther than AqFSC [42,43]. Therefore lignans in FSC un-
likely contribute to the amelioration of fatty liver induced
by HFCBD. There are eight integrants in the water-
soluble fraction of FSC through spectral analysis, they
include protocatechuic acid, quinic acid, 2-methyl citrate,
5-hydroxymethyl-2-furancarboxaldehyde, zingerone glu-
coside, thymoquinol 2-glu-coside, thymoquinol 5-glucoside,
daucosterol [44]. EtFSC mainly contains lignans including
schizandrin A, B, and C; schizandrol A and B; gomisin B,
C, D, E, G, H, J, and N; tigloylgomisin H; and angeloylgo-
misin H etc. [45].
Fenofibrate has been prescribed for patients with dyslipide-
mia in the US since 1998. The lipid-lowering action of fenofi-
brate in the blood (or likely in liver tissue too) has been
shown to be mediated by the activation of PPAR-alpha and
lipoprotein lipase, as well as suppression of apoliprotein C-III,
fatty acid synthase, acetyl CoA carboxylase, and cholesterol
absorption, etc. [46-49]. Recently, it is revealed that fenofi-
brate induces the activity of enzymes in the tricarboxylic acid
cycle [50]. It is unclear whether this may contribute to weight
loss induced by fenofibrate. Although active ingredient of
FSC (schisandrin B) and its related analogs (bifendate, and
bicyclol) have been shown to affect lipid metabolism [51-54],
the mechanism underlying the lipid-lowering effect of AqFSC
and EtFSC remains to be elucidated.
Conclusion
Dietary supplementation with AqFSC or EtFSC and feno-
fibrate ameliorated the fatty liver condition in HFCBD-fed
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HDL and LDL levels in HFCBD-fed mice. EtFSC, but not
AqFSC, supplementation reduced serum ALT activity in
both ND- and HFCBD-fed mice. Although fenofibrate
produced a potent hypolipidemic action, it caused hepato-
toxicity and hepatomegaly. Naturally-occurring ingredi-
ents from medicinal plants such FSC may be a safe
alternative for the management of fatty liver.
Materials and methods
Plant material and extraction procedure
FSC, the fruit of Schisandra chinensis (Turcz.) Baill., was
purchased from the Anguo Chinese herbs market and
authenticated by Dr. H. Dong. For the preparation of the
aqueous extract of FSC (AqFSC), 470 g of powdered
FSC was boiled in ten volumes of distilled water for 1 h.
The procedure was repeated twice with 8 volumes of
water. The pooled aqueous extract was filtered through
gauze cloth and the filtrate was evaporated by heating to
obtain 200 ml of pre-AqFSC. The pre-AqFSC (200 ml)
was then precipitated twice with ten and five volumes of
95% ethanol for 12 h at 5°C. Eighty-nine g of AqFSC
(i.e., 5.28 g of herb for every 1 g of AqFSC) was finally
obtained and stored at 4°C until use. For the preparation
of the ethanolic extract of FSC (EtFSC), FSC was
crushed into small pieces and extracted twice with five
volumes of 80% (v/v, in H2O) ethanol under reflux. The
pooled extract was filtered by filter paper and concen-
trated under reduced pressure by rota-evaporation to
obtain EtFSC, with a yield of 50% (w/w) (i.e., 2 g of herb
for every 1 g of extract), and stored at 4°C until use.
Chemicals and reagents
Cholesterol (certificate no. 041103) and bile salt (certifi-
cate no. 000710) were obtained from Beijing Chemical
Reagent Co. (Beijing, China). Fenofibrate (certificate no.
0405030) was bought from Beijing Yongkang Medical Ltd.
(Beijing, China). Assay kits for hepatic TC and TG were
bought from Zhongsheng Beikong Bio-technology and
Science Inc. (Beijing, China). Serum TC, TG, high-density
lipoprotein cholesterol (HDL), and low-density lipoprotein
cholesterol (LDL) levels as well as alanine aminotransfer-
ase (ALT), and aspartate aminotransferase (AST) activ-
ities were measured using commercial kits from Beijing
Leadman Biochemistry CO., Ltd. (Beijing, China).
Animal treatment
Male ICR mice (Grade II, certificate No. SCXK(jing) 2006–
0009), weighing 18–20 g, were supplied by Vital River Lab
Animal Co. Ltd. (Beijing, China). All animals were main-
tained on a 12 h (light on 700–1900 h) light-dark cycle at
20–21, with a relative humidity of 50–55%. They were
allowed free access to water and food. Animals were
divided into 6 groups of 10 animals in each: (1) mice fednormal diet (ND); (2) and (3) mice fed diet supplemented
with 1% (w/w) and 4% AqFSC, respectively; (4) and (5)
mice fed diet supplemented with 1% and 4% EtFSC, re-
spectively; and (6) mice fed diet supplemented with 0.1%
fenofibrate. In addition, the effect of FSC extracts on mice
with hypercholesterolemia induced by high-fat/cholesterol/
bile salt diet (HFCBD, 10/1/0.3%, w/w) was also investi-
gated. Seventy mice were randomized into seven groups of
10 animals in each: (1) mice fed ND; (2) mice fed HFCBD;
(3)-(6) mice fed HFCBD supplemented with AqFSC or
EtFSC diet at 1% and 4% concentrations; (7) mice fed
HFCBD supplemented with fenofibrate at 0.1%. Mice were
fed ND or HFCBD supplemented with AqFSC/EtFSC or
fenofibate for 13 days. Then blood and liver tissue samples
were obtained from ether-anesthetized animals which had
been fasted for 6 h (from 600 to 1200). Hepatic index was
estimated from the ratio of total liver weight to body
weight. All experimental procedures were approved by the
University Committee on Research Practice in Beijing Uni-
versity of Chinese Medicine.Biochemical analysis
Serum and liver samples were obtained 24 h after the
last day of the experiment. Serum samples were pre-
pared by centrifuging the whole blood obtained from the
orbital vein for 8 min at 2000 × g and stored at −70°C
until use for biochemical analyses. The liver tissue sam-
ple was homogenized in 9 volumes of 0.9% (w/v) NaCl
solution by two 10-s bursts of a tissue disintegrator at
13,500 rpm, and the homogenate was then centrifuged
at 2000 × g for 15 min to obtain the supernatants. Ten
and 40 μl of the hepatic supernatant were used to deter-
mine the TG and TC levels, respectively, according to
the manufacture’s instructions. Serum lipid profiles such
as TC, TG, HDL, and LDL, as well as ALT and AST ac-
tivities were determined using LM280 automatic clinical
chemistry analyzer (Leadman Group Co., Ltd.)Statistical analysis
All values are expressed as means ± S.E.M. Data were
analyzed by 1-way ANOVA using SPSS (version 12) stat-
istical analysis program, and then differences among
means were analyzed using Duncan’s test. p < 0.05 was
considered significant.
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